Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CAR lentiviral vector is a gene therapy tool used to genetically engineer T cells to express a chimeric antigen receptor (CAR) directed against the human CD19 antigen. The vector is typically a self-inactivating (SIN) lentivirus, often pseudotyped with the vesicular stomatitis virus G glycoprotein (VSV-G), which delivers a transgene cassette encoding an anti-CD19 single-chain variable fragment (scFv) linked to intracellular signaling domains such as 4-1BB (CD137) or CD28 and the CD3ζ chain. Once transduced, the patient's T cells (CAR-T cells) can specifically recognize and eliminate CD19-expressing B cells. This platform is widely utilized in the development of therapies for B-cell malignancies, including acute lymphoblastic leukemia (ALL) and B-cell lymphomas, as well as for refractory systemic autoimmune diseases where B-cell depletion is therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CD19-CAR lentiviral vector.